Urology Medical News about phosphodiesterase

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Factors associated with phosphodiesterase type 5 inhibitor treatment satisfactions: results of patient interrogation
The Aging Male, 06/30/09

Cimen S et al. - Therapy with PDE5 inhibitors is an effective means of ED treatment. The importance of doctor-patient communication should be considered, and the patient should be advised for adaptation to follow-up program. High drug cost is a significant predictor of patient compliance to treatment continuation.

<< Previous
A phase III clinical trial of exercise modalities on treatment...

Next >>
Topical overactive bladder gel found well-tolerated, effective

Platelet Cyclic Guanosine Monophosphate as a Biomarker of Phosphodiesterase Type 5 Inhibitor Efficacy in the Treatment of Erectile Dysfunction: A Randomized Placebo-Controlled Study
European Urology, 11/05/09 Relevance Score: 85%

Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysis
Annals of Internal Medicine, 10/23/09 Relevance Score: 82%

A Randomised, Double-Blinded, Placebo-Controlled Study of the Phosphodiesterase Type 5 Inhibitor Sildenafil for the Treatment of Preeclampsia
Hypertension in Pregnancy, 10/30/09 Relevance Score: 80%

Guidelines Urge Use of Erectile Dysfunction Drugs
Internet Source, 10/29/09 Relevance Score: 80%

Studies show Viagra, other drugs outperform hormone treatment
Internet Source, 10/21/09 Relevance Score: 80%